| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Business Officer
1 company
Joseph Baroldi is EVP, Chief Business Officer at IONS. Joseph Baroldi's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $189K at current prices.
Historically, Joseph Baroldi's trades have earned a middling insider score of 65/100 across 18 rated trades. Over a 12-month horizon, 70.0% of those trades were profitable, with an average 12-month return of +2.4%.
The IONS filings lean toward selling, a net 113,159 shares.
Joseph Baroldi has 27 Form 4 filings on record from February 2021 to June 2026, across 2 companies: EVP, Chief Business Officer at Ionis Pharmaceuticals (IONS), 2022–2026; Chief Operating Officer at Avidity Biosciences (RNA), 2021.
The 74 reported transactions were 25 open-market sales, 25 option or other derivative awards, 23 option exercises and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $7.1M.
The largest open-market sale was 32,800 shares of IONS at an average $59.34 on September 3, 2025, about $1.9M. Twelve months later IONS was down 4%.
8 of the 16 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 8 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Business Officer | Sale+OE10b5-1 | 5,635 | $80.16 | $451,698.78 | -54.7% | -46.0% | - | |
| Apr 28, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Business Officer | Sell10b5-1 | 1,626 | $71.79 | $116,726.80 | -3.5% | -22.0% | - | |
| Apr 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Business Officer | Sale+OE | 5,619 | $74.56 | $418,952.64 | -10.8% | -27.3% | - | |
| Mar 4, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Business Officer | Sale+OE10b5-1 | 6,659 | $79.74 | $530,986.62 | -12.7% | -8.2% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439,364.10 | -10.4% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Business Officer | Sale+OE | 8,056 | $75.75 | $610,276.47 | -15.1% | -1.4% | - | |
| Oct 6, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Business Officer | Sell10b5-1 | 1,625 | $69.37 | $112,725.11 | -5.1% | +13.8% | -36.3% | |
| Oct 2, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Business Officer | Sale+OE10b5-1 | 15,000 | $68.01 | $1,020,210.00 | -32.0% | +15.7% | -36.3% | |
| Sep 9, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Business Officer | Sale+OE10b5-1 | 11,950 | $62.16 | $742,838.29 | -27.2% | +26.6% | -13.0% | |
| Sep 5, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Business Officer | Sale+OE10b5-1 | 250 | $62.00 | $15,500.00 | -0.8% | +33.6% | -5.1% |